Literature DB >> 17220172

A new inborn error of glycosylation due to a Cog8 deficiency reveals a critical role for the Cog1-Cog8 interaction in COG complex formation.

François Foulquier1, Daniel Ungar, Ellen Reynders, Renate Zeevaert, Philippa Mills, Maria Teresa García-Silva, Paz Briones, Bryan Winchester, Willy Morelle, Monty Krieger, Willem Annaert, Gert Matthijs.   

Abstract

The hetero-octameric conserved oligomeric Golgi (COG) complex is essential for the structure/function of the Golgi apparatus through regulation of membrane trafficking. Here, we describe a patient with a mild form of a congenital disorder of glycosylation type II (CDG-II), which is caused by a homozygous nonsense mutation in the hCOG8 gene. This leads to a premature stop codon resulting in a truncated Cog8 subunit lacking the 76 C-terminal amino acids. Mass spectrometric analysis of the N- and O-glycan structures identified a mild sialylation deficiency. We showed that the molecular basis of this defect in N- and O-glycosylation is caused by the disruption of the Cog1-Cog8 interaction due to truncation. As a result, Cog1 deficiency accompanies the Cog8 deficiency, preventing assembly of the intact, stable complex and resulting in the appearance of smaller subcomplexes. Moreover, levels of beta1,4-galactosytransferase were significantly reduced. The defects in O-glycosylation could be fully restored by transfecting the patient's fibroblasts with full-length Cog8. The Cog8 defect described here represents a novel type of CDG-II, which we propose to name as CDG-IIh or CDG caused by Cog8 deficiency (CDG-II/Cog8).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220172     DOI: 10.1093/hmg/ddl476

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  55 in total

Review 1.  Retrograde vesicle transport in the Golgi.

Authors:  Nathanael P Cottam; Daniel Ungar
Journal:  Protoplasma       Date:  2011-12-12       Impact factor: 3.356

2.  Neurology of inherited glycosylation disorders.

Authors:  Hudson H Freeze; Erik A Eklund; Bobby G Ng; Marc C Patterson
Journal:  Lancet Neurol       Date:  2012-05       Impact factor: 44.182

3.  Identification of the first COG-CDG patient of Indian origin.

Authors:  Bobby G Ng; Vandana Sharma; Liangwu Sun; Eva Loh; Wanjin Hong; Stacey K H Tay; Hudson H Freeze
Journal:  Mol Genet Metab       Date:  2010-11-24       Impact factor: 4.797

Review 4.  Role of the conserved oligomeric Golgi (COG) complex in protein glycosylation.

Authors:  Richard D Smith; Vladimir V Lupashin
Journal:  Carbohydr Res       Date:  2008-02-02       Impact factor: 2.104

Review 5.  Localization of Golgi-resident glycosyltransferases.

Authors:  Linna Tu; David Karl Banfield
Journal:  Cell Mol Life Sci       Date:  2009-09-01       Impact factor: 9.261

6.  Conserved oligomeric Golgi complex specifically regulates the maintenance of Golgi glycosylation machinery.

Authors:  Irina D Pokrovskaya; Rose Willett; Richard D Smith; Willy Morelle; Tetyana Kudlyk; Vladimir V Lupashin
Journal:  Glycobiology       Date:  2011-03-18       Impact factor: 4.313

7.  Deficiency of Subunit 6 of the Conserved Oligomeric Golgi Complex (COG6-CDG): Second Patient, Different Phenotype.

Authors:  S Huybrechts; C De Laet; P Bontems; S Rooze; H Souayah; Y Sznajer; L Sturiale; D Garozzo; G Matthijs; A Ferster; J Jaeken; P Goyens
Journal:  JIMD Rep       Date:  2011-11-02

8.  Mislocalization of phosphotransferase as a cause of mucolipidosis III αβ.

Authors:  Eline van Meel; Yi Qian; Stuart A Kornfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

Review 9.  Glycosylation Quality Control by the Golgi Structure.

Authors:  Xiaoyan Zhang; Yanzhuang Wang
Journal:  J Mol Biol       Date:  2016-03-05       Impact factor: 5.469

10.  Golgi function and dysfunction in the first COG4-deficient CDG type II patient.

Authors:  Ellen Reynders; François Foulquier; Elisa Leão Teles; Dulce Quelhas; Willy Morelle; Cathérine Rabouille; Wim Annaert; Gert Matthijs
Journal:  Hum Mol Genet       Date:  2009-06-03       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.